Biocortech is completing clinical proof of concept of its in vitro diagnostics tests for disease management of brain disorders and is interested in collaborating on their regulatory development, industrialization, marketing and commercialization, with industry partner(s) having a franchise in in vitro diagnostic market. Biocortech contemplates possibilities to develop and commercialize diagnostic tests for niche markets.
Biocortech is also interested in exploring potential partnerships with pharmaceutical companies in the field of translational research on depression, schizophrenia and neuro-degenerative diseases (Alzheimer disease).
Toxicology Screening Platform
Biocortech is offering a drug screening service that gives customers a way to prioritize or discard compounds or candidate drugs early by predicting 5HT2cR editing-related potential central neurotoxicity of compounds, by comparing the 5HT2cR editing profiles induced by those compounds in vitro and/or in vivo to the profile signing occurrence of suicide.
Biocortech completed such a screening for more than 60 reference drugs from various therapeutic classes. Beyond such screening, Biocortech may engage in drug discovery collaboration, aiming at generating novel compounds inducing favorable 5HT2cR editing profiles.
Biocortech is licensing out one proprietary molecule with a favorable 5HT2cR mRNA editing profile that displays both noradrenergic and serotonergic pharmacological activity.